METTL3 and hepatocellular carcinoma: In HCC, SOCS is recognized and degraded as a target of m6A writer methyltransferase-like 3 (METTL3)-mediated m6A modification, thereby abrogating its inhibitory effect on the JAKs-STAT1 pathway (53, 54).